Aurora Cannabis Revenue Rises 9% on Sales Growth
International medical sales offset Canadian declines and consumer cannabis losses in the fiscal second quarter ended Sept. 30.
Updated on Nov. 7, 2026 in Economic Indicators
Aurora Cannabis reported net revenue of C$86 million for the quarter ended Sept. 30, up 9% from C$78.8 million a year earlier. Adjusted net income fell to C$3.1 million from C$12 million.
Why it matters
The revenue gain was driven by growing international medical demand, while profitability weakened as operating costs rose. The divergence shows the company's results depend heavily on markets outside Canada.
Net revenue reached C$86 million, up 9% from C$78.8 million a year earlier, while adjusted net income fell to C$3.1 million from C$12 million. International medical cannabis revenue rose 44% to C$61.4 million, though the filing does not say whether this pace will hold in later quarters.
The players
Aurora Cannabis
A Canadian cannabis producer with medical and consumer operations in Canada and several international markets, including Germany and Poland.
The details
International medical cannabis revenue rose 44% to C$61.4 million, driven by higher sales in Germany and Poland tied to increased patient demand. Canadian medical cannabis revenue fell 24% to C$21.2 million, mainly due to changes to the federal reimbursement program, and consumer cannabis revenue dropped to C$1.6 million from C$6.9 million.
Timeline
Sept. 30: End of the fiscal second-quarter reporting period
Macro View
The 24% drop in Canadian medical revenue traces directly to changes in Canada's federal medical cannabis reimbursement program. That pattern reflects how government reimbursement policy can reshape producer revenue even as overseas demand grows.
Patients relying on Canadian medical cannabis may see changes tied to the reimbursement program shifts. Investors weighing cannabis stocks should note that the quarter's earnings declined even as revenue grew.
The takeaway
Revenue growth does not guarantee profit growth, so readers should look beyond top-line figures when evaluating cannabis producers. Watching how reimbursement policy and international demand evolve will shape future results.
Further reading
For broader context on financial reporting trends, explore Economic Indicators.
Source note: This article includes information reported by TokenPost.
